As phase 3 clinical trials push the drug development frontier forwards, artificial intelligence refines biomarker analysis, and genetically defined kidney disease becomes targetable: 2019 is an exciting time for CKD drug development.
Chronic Kidney Disease Drug Development (CKD3) is a uniquely focused conference that unites key opinion leaders in this field to identify and discuss the critical factors determining the success of current CKD pipelines and significantly impact the standard of care for this huge unmet medical need.
Bringing together leading experts from innovative biotechs, large pharma, academia and key service provider companies, CKD3 will present comprehensive insight into the cutting edge progress of CKD drug development research.
Attend this focused summit to learn:
- Unique insights directly from front line organizations and principle investigators to better align your own research with the pace and direction of your peers
- Understanding of next generation techniques, modalities, and machine learning to optimize your candidate development from discovery and in vitro
studies through to phase 3
- Valuable new and strengthened connections with key thoughts leaders to advise and steer your pipeline’s acceleration
Download the full event guide here to view the complete agenda and speaker line-up.